Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities - Wikidata - wikimedia - TriplyDB

Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities

Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities

http://www.wikidata.org/entity/Q27490426

about

DDX6 (Rck/p54) is required for efficient hepatitis C virus replication but not for internal ribosome entry site-directed translation Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122 Viral hepatitis in Hawai'i--differing perspectives The SR-BI partner PDZK1 facilitates hepatitis C virus entry.Hepatitis C virus genomic RNA dimerization is mediated via a kissing complex intermediate.Induction and evasion of innate antiviral responses by hepatitis C virus.A disulfide-bonded dimer of the core protein of hepatitis C virus is important for virus-like particle production Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems.Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors Induction of broadly neutralising HCV antibodies in mice by integration-deficient lentiviral vector-based pseudotyped particles Reproduction in vitro of a quasispecies from a hepatitis C virus-infected patient and determination of factors that influence selection of a dominant species.TnBP⁄Triton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus.Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus Catalytic metallodrugs based on the LaR2C peptide target HCV SLIV IRES RNA.Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients.Adaptive immunity to the hepatitis C virus.In-cell selectivity profiling of membrane-anchored and replicase-associated hepatitis C virus NS3-4A protease reveals a common, stringent substrate recognition profile.Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system.Hepatitis C virus: propagation, quantification, and storage.Catalytic metallodrugs targeting HCV IRES RNA.Assessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype 1b.

P2860

Q24609953-BCE84EC4-52C3-4509-99BB-513A2AA61F63 Q24609988-FA0DEEF5-BC39-4DEA-85F1-4D688D719C9C Q28729042-23C835BF-14C0-4EBF-AAB5-13CBF904A281 Q33719403-C5D44335-EBA6-4965-91C1-91ACF00BBA4B Q33799124-B707A266-BAA8-4D71-8AB8-3DF5D075D334 Q34003764-7C5ED8BF-BBAF-4BAD-A492-0B04782C8482 Q34120119-EEA8FA18-AB4A-472A-9D44-C3282182263D Q34288777-6BCE3154-6854-4576-9E8C-2CC74D754117 Q34530512-CA43139C-33FD-4AD2-8B2C-BFDCE08E815B Q34693362-A50CC5FA-474A-4E3E-936B-4908EBBFEC75 Q34742576-FC017005-2753-4FA9-AAE5-C1F07DCECA81 Q35058574-74E42938-FFF9-4964-98EA-FA0772440D54 Q35164008-40D03932-3533-441D-8450-52E9CD3AB05C Q35846078-78476749-8A7D-4641-9629-500B1F9282E7 Q36812745-804913E1-F211-4863-A91A-8D5B704443FF Q36827155-A8A30552-E34F-4F68-800A-6F029FABDBA5 Q37805839-70557A4B-4F0A-4F33-AE63-645C0475F5AF Q39508229-7DFCC5D1-015E-4AA8-A064-9C4C982771AA Q39584985-34B6AF6A-B3CF-47D6-97A1-40F7C9791C69 Q39635405-5B747E0E-0ADB-4F35-BA47-BA05FE41F302 Q42977821-B42FD92C-EA05-4C63-9F07-C7F1A1181877 Q43047642-D999B4C5-50B8-4B19-AF3F-0E4816809C65

P2860

Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities

http://www.wikidata.org/entity/Q27490426

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Hepatitis C: recent successes ...... improved treatment modalities

@ast

Hepatitis C: recent successes ...... improved treatment modalities

@en

Hepatitis C: recent successes ...... improved treatment modalities

@nl

type

label

Hepatitis C: recent successes ...... improved treatment modalities

@ast

Hepatitis C: recent successes ...... improved treatment modalities

@en

Hepatitis C: recent successes ...... improved treatment modalities

@nl

prefLabel

Hepatitis C: recent successes ...... improved treatment modalities

@ast

Hepatitis C: recent successes ...... improved treatment modalities

@en

Hepatitis C: recent successes ...... improved treatment modalities

@nl

P1433

Q27490426-D038B72B-65A4-46B8-8029-1A1E72FA844B

P1476

Q27490426-A3498439-7628-4278-84FD-EA4EB09B8F8E

P2093

Q27490426-6BA793CB-0DBB-4725-9568-C3E8F3852025

Q27490426-A2BA9FB4-9FAF-4DED-940D-4CC18DDFFEEF

Q27490426-DD516F1B-3750-4775-9A19-CFEA7DBB01AD

P2860

Q27490426-01203677-D793-4FB0-AE69-BFDE4798D783

Q27490426-0BF6AD42-F4E0-4906-8A72-9F31B7621892

Q27490426-190B1C45-11EA-4B41-A599-593E598ADCC3

Q27490426-19F13147-CE32-4AC6-B149-504A089928AD

Q27490426-1CA9C7DA-2C71-4FD4-BE07-80C9A0868C29

Q27490426-1F6C1A94-CCDD-40C4-B980-7DB7DB28046F

Q27490426-2A7DD64A-B809-4F34-913F-754003E32474

Q27490426-2EC9B3BB-5497-43DE-8BD5-89C71F26C221

Q27490426-3110D50B-BC2E-4CED-8B11-84DCEBCFEFA6

Q27490426-3A2850E5-A2A3-4B15-84E6-762B2F4BD450

P304

Q27490426-602C321C-3F85-43E7-9703-57A0F64B2ED2

P31

Q27490426-90D43351-4A28-4BA2-A631-0EFB1632131A

P356

Q27490426-0D284837-39C2-4052-ABA3-B24095EE8672

P433

Q27490426-F00F564A-D76A-46AB-9B82-63AEABADB5B9

P478

Q27490426-E7F44220-6D97-450E-A090-0562A87C4212

P577

Q27490426-B558968A-BE1B-4889-9FF8-BC9E3D62E1E4

P5875

Q27490426-3458BDE3-5B8B-428C-ABBC-11AC0BDFBE24

P698

Q27490426-CC5661AB-8FA3-470F-857F-0BD0981610C3

P921

Q27490426-46D9F4E3-953C-4E25-8B9F-E5BDB9E8FF0B

P932

Q27490426-CB0901E2-2677-4E21-96FE-05D014D8FFF4

P356

J.COPH.2009.08.008

P1433

Current Opinion in Pharmacology

P1476

Hepatitis C: recent successes ...... improved treatment modalities

@en

P2093

Robert E Lanford

http://www.w3.org/2001/XMLSchema#string

Stanley M Lemon

http://www.w3.org/2001/XMLSchema#string

Tetsuro Shimakami

http://www.w3.org/2001/XMLSchema#string

P2860

Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus

Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.

Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

RNA translocation and unwinding mechanism of HCV NS3 helicase and its coordination by ATP

Characterization of Hepatitis C Virus Subgenomic Replicon Resistance to Cyclosporine In Vitro

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

Interferon signaling and treatment outcome in chronic hepatitis C

Lack of response to exogenous interferon-α in the liver of chimpanzees chronically infected with hepatitis C virus

P304

537-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.COPH.2009.08.008

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26819871

http://www.w3.org/2001/XMLSchema#string

P698

19762279

http://www.w3.org/2001/XMLSchema#string

P921

P932

2782474

http://www.w3.org/2001/XMLSchema#string